AR040623A1 - Vacuna contra el virus de la aftosa. - Google Patents

Vacuna contra el virus de la aftosa.

Info

Publication number
AR040623A1
AR040623A1 AR20020101563A ARP020101563A AR040623A1 AR 040623 A1 AR040623 A1 AR 040623A1 AR 20020101563 A AR20020101563 A AR 20020101563A AR P020101563 A ARP020101563 A AR P020101563A AR 040623 A1 AR040623 A1 AR 040623A1
Authority
AR
Argentina
Prior art keywords
construct
ifn
vaccine
vector
fmdv
Prior art date
Application number
AR20020101563A
Other languages
English (en)
Inventor
Marvin J Grubman
Jarasvech Chinsangaram
Marla Koster
Mauro P Moraes
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Publication of AR040623A1 publication Critical patent/AR040623A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vacuna para la protección temprana de los animales susceptibles contra FMDV mediante la expresión de IFN-alfa o -beta. La vacuna comprende una composición teniendo la construcción o el vector conteniendo la construcción y un portador fisiológicamente aceptable, como fosfato salino amortiguado, fisiológicamente salino o medio de cultivo. La construcción también contiene secuencias las cuales codifican IFN-alfa o -beta, o una combinación de ello. Secuencias las cuales codifican un apropiado FMDV antígeno están también incluidas en la construcción para una co-administración conveniente de ambos antígenos IFN y FMDV o como una construcción separada. Reivindicación 7: El vector de acuerdo con la reivindicación 5 caracterizado porque el vector comprende un vector de transferencia de gen viral. Reivindicación 23: Un método para proteger animales susceptibles a la enfermedad de la fiebre aftosa comprendiendo la inoculación de dichos animales con una dosis efectiva de la vacuna de cualquiera de las reivindicaciones 15-22.
AR20020101563A 2001-04-26 2002-04-29 Vacuna contra el virus de la aftosa. AR040623A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28634501P 2001-04-26 2001-04-26
US10/128,463 US8058248B2 (en) 2001-04-26 2002-04-24 Foot and mouth disease virus vaccine comprising interferons

Publications (1)

Publication Number Publication Date
AR040623A1 true AR040623A1 (es) 2005-04-13

Family

ID=26826603

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20020101563A AR040623A1 (es) 2001-04-26 2002-04-29 Vacuna contra el virus de la aftosa.

Country Status (13)

Country Link
US (1) US8058248B2 (es)
EP (1) EP1389043B1 (es)
JP (1) JP2004530677A (es)
CN (1) CN100422322C (es)
AR (1) AR040623A1 (es)
AT (1) ATE437656T1 (es)
AU (1) AU2002303503B2 (es)
BR (1) BR0209251A (es)
CA (1) CA2445266A1 (es)
DE (1) DE60233127D1 (es)
MX (1) MXPA03009763A (es)
NZ (1) NZ529305A (es)
WO (1) WO2002087336A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629163C (en) * 2005-11-10 2017-03-21 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
CN100572541C (zh) * 2007-05-28 2009-12-23 中国农业科学院兰州兽医研究所 口蹄疫病毒双效疫苗载体、其制备方法及应用
US8846057B2 (en) * 2010-01-19 2014-09-30 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant live attenuated foot-and-mouth disease (FMD) vaccine containing mutations in the L protein coding region
CN102226198B (zh) * 2011-04-25 2016-04-06 中国农业科学院兰州兽医研究所 对口蹄疫病毒有抑制作用的干扰靶序列
GB201111183D0 (en) * 2011-06-30 2011-08-17 Animal Health Inst Peptide
CN102988970B (zh) * 2011-09-19 2014-06-18 内蒙古必威安泰生物科技有限公司 口蹄疫纯化疫苗及其制备方法和应用
CN102363043B (zh) * 2011-10-09 2013-05-01 中国农业科学院兰州兽医研究所 一种猪用c型口蹄疫基因工程疫苗佐剂及其制备方法
KR101329348B1 (ko) * 2012-05-31 2013-11-15 대한민국 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스
CN103592441B (zh) * 2013-10-29 2015-06-17 王明丽 一种重组猪干扰素ɑ双抗体夹心法免疫胶体金检测试纸条的制备方法
CN106546747B (zh) * 2016-10-31 2019-03-01 江苏众红生物工程创药研究院有限公司 一种干扰素生物学活性的检测方法
CN108103034B (zh) * 2017-12-15 2022-06-24 云南农业大学动物医学院 同时表达A型、O型和Asia-1型口蹄疫病毒VP1基因重组腺病毒、构建方法及应用
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831023A (en) 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US4795436A (en) 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US4732971A (en) * 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CN1054544C (zh) * 1993-10-21 2000-07-19 复旦大学 家畜口蹄疫病毒多肽疫苗及其制备方法
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6221361B1 (en) 1995-01-19 2001-04-24 Syntro Corporation Recombinant swinepox virus
US5612040A (en) * 1995-04-07 1997-03-18 The United States Of America As Represented By The Secretary Of Agriculture Non-infectious foot-and-mouth disease viruses
US5824316A (en) * 1996-05-24 1998-10-20 The United States Of America As Represented By The Secretary Of Agriculture Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines
DE19638044A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Immunogene Peptide von Maul- und Klauenseuchen-Viren
KR20000049243A (ko) * 1996-10-18 2000-07-25 이. 엘. 나가부샨, 리차드 비. 머피 인터페론-알파 핵산의 운반 및 발현 방법 및 이를 위한 조성물
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
EA003256B1 (ru) * 1997-08-29 2003-02-27 Байоджен, Инк. СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ IN VIVO ПРИ ПОМОЩИ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ β-ИНТЕРФЕРОН
AU1463300A (en) * 1998-11-09 2000-05-29 Nader G. Abraham Retroviral vectors encoding interferon alpha and uses thereof
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes

Also Published As

Publication number Publication date
CN1533242A (zh) 2004-09-29
MXPA03009763A (es) 2004-07-30
NZ529305A (en) 2005-08-26
WO2002087336A1 (en) 2002-11-07
BR0209251A (pt) 2005-02-09
ATE437656T1 (de) 2009-08-15
AU2002303503B2 (en) 2007-09-20
US8058248B2 (en) 2011-11-15
US20030171314A1 (en) 2003-09-11
CN100422322C (zh) 2008-10-01
DE60233127D1 (es) 2009-09-10
JP2004530677A (ja) 2004-10-07
EP1389043A1 (en) 2004-02-18
CA2445266A1 (en) 2002-11-07
EP1389043A4 (en) 2004-09-08
EP1389043B1 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
Roberts et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
AR040623A1 (es) Vacuna contra el virus de la aftosa.
Goldufsky et al. Oncolytic virus therapy for cancer
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DE69529748D1 (de) Polynukleotide vakzine gegen den papilloma virus
PE20030285A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
NO20015073L (no) Vaksiner
HRP20040195B1 (hr) Cjepivo protiv bolesti zapadnoga nila
ATE417097T1 (de) Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe
BR0316346A (pt) Vacina para vìrus do nilo ocidental
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
AR041964A1 (es) Vacuna de vhc que comprende un polinucleotido
WO2017004567A1 (en) Compositions and methods for combination therapy with dengue virus and dendritic cells
DE602004028029D1 (en) Rwendung
IL153775A0 (en) Immunizing fish against viral infection
Abedi et al. Rabies vaccine: Recent update and comprehensive review of in vitro and in vivo studies
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
Zinkernagel Immunity, immunopathology and vaccines against HIV?
SE9903534D0 (sv) Vaccin
Hsieh et al. The effect of co-administration of DNA carrying chicken interferon-γ gene on protection of chickens against infectious bursal disease by DNA-mediated vaccination
Woolard et al. Viral vaccines and CTL response
TW200509964A (en) VP1 of foot-and-mouth disease virus
Kim et al. Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG)
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
CO5300406A1 (es) Vacuna

Legal Events

Date Code Title Description
FB Suspension of granting procedure